Ask someone in a compounding pharmacy why two peptides keep showing up in the same sentence, and the answer usually has less to do with what they do and more to do with when researchers started asking about them together.
BPC-157 and TB-500 get paired often enough in nomination files and advisory hearings that it’s easy to assume their research histories run in parallel. They don’t, not exactly.
Where the Two Peptide Literatures Diverge
BPC-157 traces back to research into a protein found in gastric juice. Early animal work centered on gut lining protection. Later studies extended that interest into tendon and ligament injury, largely because a similar local signaling process seemed to show up in both settings.
TB-500 traces back to thymosin beta-4, a protein with a much wider natural distribution in the body. Its research base leans on cell migration, how tissue responds when cells need to move into a damaged area rather than stay anchored to one location.
That distinction, local signaling versus broader cell movement, is the closest thing to a throughline across the two literatures. It doesn’t make the peptides interchangeable. It mostly explains why they’ve been studied for some of the same injury models.
Comparing the Research Focus at a Glance
| BPC-157 | TB-500 | |
| Preclinical focus | Gut lining protection, tendon and ligament repair, local vessel growth | Cell migration, wound response, broader tissue distribution |
| Typical study settings | Rodent models of gut and tendon injury | Rodent and cell culture models of wound and muscle tissue |
| FDA 503A history | Category 2 designation in 2023, removed from Category 2 in April 2026 | Category 2 designation in 2023, removed from Category 2 in April 2026 |
| July 2026 PCAC vote | Recommended for the 503A Bulks List, 8 to 6, one abstention | Recommended for the 503A Bulks List, 8 to 6, one abstention |
| Current FDA status | Not an approved drug. Not a legal over the counter product | Not an approved drug. Not a legal over the counter product |
The Regulatory Path Behind Both Names
The path for BPC-157 and TB-500 has run on a tangled timeline, and it’s worth knowing before reading too much into any research summary built around either one.
Both were placed on the FDA’s Category 2 list of bulk drug substances in 2023, a category reserved for substances the agency considers to carry significant safety concerns for compounding. That placement effectively blocked compounding pharmacies from preparing either peptide for patients.
In April 2026, the FDA removed both from Category 2, following withdrawal of their original compounding nominations. Removal from Category 2 isn’t approval. Neither peptide moved onto Category 1, the list compounding pharmacies are actually permitted to draw from.
Then in July 2026, the FDA’s Pharmacy Compounding Advisory Committee reviewed both for possible inclusion on the 503A Bulks List, the list that would make compounding legal under federal law. The committee voted in favor of both, breaking with the FDA’s own staff recommendation against listing them.
A favorable committee vote isn’t a rule change. Formal rulemaking still has to happen before either peptide could legally be compounded, and that process typically runs a year or more. Right now, neither BPC-157 nor TB-500 is an FDA-approved drug, and neither has legal status as an over the counter product.
What Shared Interest Doesn’t Establish
Two peptides showing up in the same hearing, or the same nomination cycle, doesn’t mean their research supports the same conclusions. Much of the overlap here is circumstantial. Both got nominated around the same period, both landed in the same regulatory review.
The underlying laboratory work still points in somewhat different directions. Treating one peptide’s animal data as evidence for the other blurs a line the research itself hasn’t blurred.
What actually connects BPC-157 and TB-500 in the literature isn’t a shared mechanism so much as a shared timeline. Their names have moved through the same regulatory documents, the same advisory hearings, the same review cycles. The biology underneath tells a more separate story than the paperwork suggests.
